CA
NZ
UK
AU
IND
US
Aspire-Lakewood Holdings, Inc. (NASDAQ:ASBP) has changed its independent registered public accounting firm, dismissing Turner Stone & Company, LLP and engaging CBIZ CPAs P.C., according to a Form 8-K filed September 29, 2026. Both steps took effect on September 24, 2026.
Atossa Therapeutics, Inc. (NASDAQ:ATOS) disclosed in a Form 8-K dated September 29, 2026 that itsBoard of Directorsapproved the issuance of contingent value rights, or CVRs, to holders of its common stock. The rights are tied to the possible monetization of a rare pediatric disease …
Bone Biologics Corp (NASDAQ:BBLG)'s stockholders approved a reverse stock split at a ratio to be set by the board between 1-for-2 and 1-for-10, and approved the issuance of common stock underlying certain warrants under Nasdaq Rule 5635(d), at the company's annual meeting on September …
Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR), a Singapore-based wound-care company listed onNasdaqunder the symbol CUPR, reported in a Form 6-K filed on September 29, 2026 that the underwriter of its recent public offering has exercised its over-allotment option. The company sold 648,373 additional Class A …
Enlivex Ltd. (NASDAQ:ENLV) has called an Extraordinary General Meeting of shareholders for October 14, 2026 to vote on a single proposal: a 1-for-16 reverse split of its ordinary shares. The Israeli company, whose shares trade onNasdaqunder the symbol ENLV and on the Tel Aviv …
Ensysce Biosciences, Inc. (NASDAQ:ENSC) has amended the terms of its Series C Non-Voting Convertible Preferred Stock to delete a provision that let holders demand cash for their shares. The amendment, which the company says became effective on filing on September 25, 2026, removes Section …
Goldenwell Biotech, Inc. (OTC:GWLL) has replaced its independent auditor, dismissing Michael Gillespie & Associates, PLLC and engaging Privatco CPA Limited, according to a Form 8-K filed September 29, 2026.
Imunon, Inc. (NASDAQ:IMNN) has exchanged $1,200,000 of principal on a note held by Streeterville Capital, LLC for 120 shares of a new Series B Preferred Stock, according to a Form 8-K filed on September 29, 2026.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) reported in a Form 8-K that stockholders approved several proposals at its 2026 annual meeting on September 22, 2026, including an increase in authorized common stock from 12.5 million to 100 million shares and board authority to carry out a …
Liminatus Pharma, Inc. (NASDAQ:LIMN) disclosed in a Form 8-K filed on September 29, 2026 that Nasdaq notified it on September 24, 2026 that it has regained compliance with the exchange's minimum bid price requirement. Nasdaq told the company that the closing bid price of …
Please wait processing your request...